Modifications of etoposide induced toxicity by 2-deoxy-D-glucose in murine tumors

Biomedicine

Volumn 24, Issue 1-2, 2004, Pages 31-44

  Gupta, Seema ^a,b   Mathur, Rohit ^a,c   Dwarakanath, B S ^a  

^a INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF DELHI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CAMPTOTHECIN; DEOXYGLUCOSE; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; FYTOSID;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CELL CYCLE; CELL DEATH; CELL GROWTH; CELL RESPIRATION; CELL STRUCTURE; CHEMOSENSITIVITY; CHROMOSOME DISORDER; DNA CONTENT; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; EHRLICH ASCITES TUMOR; FLOW CYTOMETRY; FOLLOW UP; LIGHT SCATTERING; LYMPHOMA; MALE; MICRONUCLEUS TEST; MOUSE; MOUSE STRAIN; NONHUMAN; TUMOR GROWTH;

ANIMALIA; MURINAE;

EID: 8744242407     PISSN: 09702067     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Wang, J. C. DNA topoisomerases. Ann. Rev. Biochem. 65: 635-692; 1996.
2. Champoux, J. J. DNA topoiso merases: Structure, function and mechanism. Ann. Rev. Biochem. 369-413; 2000.
3. Verga-Welsz, P. D.; Wilm, M.; Bonte, E.; Dumas, K.; Mann, M.; Becker, P. B. Chromatin remodelling factor CHRAC contains the ATPases ISWI and topoisomerase II. Nature 388: 593-602; 1997.
4. Issacs, R. J.; Davies, S. L.; Sandri, M. I.; Redwood, C.; Wells, N. J.; Hickson, I. D. Physiological regulation of eukaryotic topoisomerase II. Biochem. Biophys. Acta 1400: 121-137; 1998.
5. Holm, C.; Covey, J. M.; Kerrigan, D.; Pommier, Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res. 49: 6365-6370; 1989.
6. Hsiang, Y. H.; Hertzberg, R.; Hecht, S.; Liu, L. F. Camptothecin induces protein linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260: 14873-14875; 1985.
7. Lambert, J. M.; Fernandes, D. J. Topoisomerase II cleavable complex formation within DNA loop domains. Biochem. Pharmacol. 60: 101-109; 2000.
8. Davies, S. M.; Robson, C. N.; Davies, S. L.; Hickson, I. D. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J. Biol. Chem. 263: 17724-17729; 1988.
9. Fry, A. M.; Chresta, C. M.; Davies, S. M. et al. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res. 51: 6592-6595; 1991.
10. Chen, A. Y.; Liu, L. F. DNA topoisomerases: essential enzymes and lethal targets. Ann. Rev. Pharmacol. Toxicol. 34: 191-218; 1994.
11. Sinha B. K. Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs 49: 11-19; 1995.
12. Andoh, T.; Ishida, R. Catalytic inhibitors of DNA topoisomerase II. Biochem. Biophys. Acta 1400: 155-171; 1998.
13. Hussain, I.; Mohler, J. L.; Seigler, H. F.; Besterman, J. M. Elevation of topoisomerase I and mRNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res. 54: 539-546; 1994.
14. Osheroff, N. Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: Inhibition of DNA religation by etoposide. Biochemistry 28: 6157-6160; 1980.
15. Ross, W.; Rowe, T.; Glisson, B.; Yalowich, J.; Liu, L. Role of topoisomerase II in mediating epipodophyllotoxin induced DNA cleavage. Cancer Res. 44: 5857-5860; 1984.
16. Horwitz, S. B.; Horwitz, M. S. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res. 33: 2834-2846; 1973.
17. Giovanella, D. C.; Stehilin, J. S.; Wall, M. E. et. al. DNA topoisomerases I targeted chemotherapy of human colon cancer xenografts. Science 246: 1046-1048; 1989.
18. Giovanella, B. C.; Hinz, H. R.; Koziiski, A. J.; Stelin Jr, J. S.; Silber, R.; Potmesil, M. Complete growth inhibition of human cancer xenograft in nude mice treatment with 20-(S)-camptothecin. Cancer Res. 51: 3352-3355; 1991.
19. Giaccone, G.; Ark-Otte, J. V.; Scagliotti, G.; Capranico, G.; Valk, P. V.; Rubio, G.; Dalesio, O.; Lopez, R.; Zunino, F.; Walboomers, J.; Pinedo, H. M. Differential experience of DNA topoisomerase in non -small cell lung cancer and normal lung. Biochem. Biophys. Acta 12, 64: 337-346; 1995.
20. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: Role of ATP dependent transporters. Nature 2: 48-58; 2002.
21. Singh, S.; Dwarakanath, B. S.; Adhikari, J. S.; Chandna, S.; Mathew, T. L. Inhibition of UV induced DNA repair by the minor groove DNA ligand Hoechst-33342 in human tumor cell lines, XXV All India Cell Biology Conference, IISC, Banglore; 2001.
22. Gillano, N.; Ikhtiar, A. M.; Malinovski, O. V. The effects of inhibitors of DNA topoisomerase II on the radiosensitivity, repair and conformational changes in the chromatin in mammalian cells. Radiobiologia 33; 2: 189-196; 1993.
23. Hande, K. R. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochem. Biophys. Acta 1400: 173-184; 1998.
24. Stine, K. C.; Saylors, R. L.; Sawyer, J. R.; Becton, D. L. Secondary acute myelogenous leukemia following safe exposure to etoposide. J. Clin. Oncol. 15: 1583-1586; 1997.
25. Dingemans, A. C.; Pinedo, H. M.; Giaccone, G. Clinical resistance to topoisomerase targeted drugs Biochem. Biophys. Acta 1400: 275-288; 1998.
26. Dwarakanath, B. S.; Mathew, T. L. Approaches for improving cancer chemotherapy using topoisomerase inhibitors, XXII Annual Conference of Indian Association of Biomedical Scientists, Chennai; 2001.
27. Dwarakanath, B. S.; Adhikari, J. S.; Khaitan, D.; Mathew, T. L.; Jain, V. Modification of cellular response to topoisomerase inhibitor for improving cancer therapy. XV Asia Pacific Cancer Conference, Chennai; 1999.
28. Dwarakanath, B. S.; Khaitan, D.; Singh, S.; Mathew, T. L.; Jain, V. Two-Deoxy-D-glucose enhances the cytotoxic effects of topoisomerase inhibitors in Human Tumor Cell Lines. IUBMB Symposium on DNA Enzymes: Structure & Mechanisms. Bangalore; 2000.
29. Dwarakanath, B. S.; Khaitan, D.; Mathur, R. Inhibitors of Topoisomerases as anticancer drugs: Problems and Prospects. Emerging trends in cancer biology, J.N.U., Delhi; 2002.
30. Jha, B.; Pohlit, W. Effect of 2-deoxy-D-glucose on DNA double strand repair, cell survival and energy metabolism in euoxic Ehrlich ascites tumor cells. Int. J. Radiat. Biol. 62: 409-415; 1992.
31. Dwarakanath, B. S.; Jain, V. Enhancement of the radiation-induced damage by 2-deoxy-D-glucose in organ cultures of brain tumors. Ind. J. Med. Res. 82: 266-268; 1985.
32. Countryman, P. I.; Heddle, J. A. Production of micronuclei from chromosome aberrations in irradiated cultures of human lymphocytes. Mutat. Res. 41: 321-332; 1976.
33. Dwarakanath, B. S.; Jain, V. Energy linked modifications of the radiation response in a human glioma cell line. Int. J. Radiation Oncol. Biol. Phys. 17: 1033-1040; 1989.
34. Yanagihara, K.; Nii, M.; Kamiya, K. N.; Tauchi, H.; Sawada, S.; Seito, S. Radiation-induced apoptotic cell death in human gastric epithelial tumor cells: Correlation between mitotic death and apoptosis. Int. J. Radiat. Biol. 77: 677-685; 1995.
35. Dwarakanath, B. S.; Adhikari, J. S.; Jain, V. Hematoporphyrin derivatives potentiate the radiosensitizing effects of 2-deoxy-D-glucose in Cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 43: 1125-1133; 1999.
36. Dwarakanath, B.S.; Singh S.; Jain V. Optimization of tumour radiotherapy: Part V-Radiosensitization by 2-deox-D-glucose and DNA ligand Hoechst-33342 in a murine tumour, Ind. J. Expt. Biol. 37:8: 865-870; 1999.
37. O'Dwyer, P. J.; Jones, B. L., Alonoso, M. T. et al. Etoposide (VP-16-213). Current status of an active anticancer drug. New Engl. J. Med. 312: 692-700; 1985.
38. Woyunarwaski, J. M.; Sigmund, R. D.; Beerman, T. A. DNA minor groove binding agents interfere with topoisomerase II mediated lesions induced by epipodophyllotoxin deerivative, m-AMSA in nuclei. Biochemistry 28: 3850-3855; 1989.
39. Chen, A. Y.; Yu, C.; Gatto, B.; Liu, L. F. DNA minor groove binding ligands: A different class of mammalian DNA topoisomerase I inhibitors. Proc. Natl. Acad. Sci. (USA) 90: 8131-8135; 1993.
40. Kim, J. H.; Kolozsvary, A. et al. Potentiation of radiation response and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res. 51: 5813-5816; 1991.
41. Chen, G. L.; Yang, L.; Rowe, T. C. et al. Non-intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem. 259: 13560-13566; 1984.
42. Nittis, J. L.; Beck, W. T. Antitopoisomerase drug action and resistance. Eur. J. Cancer 32A: 958-966; 1996.
43. Osheroff N. Biochemical basis for the interactions of Type I and Type II topoisomerases with DNA. Pharmac. Ther. 41: 223-241; 1989.
44. Jain, V. K.; Kalia, V. K.; Sharma, R., Maharajan, V.; Menon, M. Effects of 2-deoxy-D-glucose on glycolysis, proliferation kinetics and radiation response of human cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 11: 943-950; 1985.
45. Jain, V.; Pohlit, W. Influence of energy metabolism on the repair of X-ray damage in living cells. III. Effect of 2-deoxy-D-glucose on the liquid holding reactivation in yeast. Biophysik 10: 137; 1973.
46. Dwarakanath, B. S.; Zolzer, F.; Chandna, S.; Bauch, T.; Adhikari, J. S.; Muller, W. U.; Streffer, C.; Jain, V. Heterogeneity in 2-deoxy-D-glucose induced modifications in energetic and radiation responses of human tumor cell lines. Int. J. Radiat. Oncol. Biol. Phys. 51: 1151-1161; 2001.
47. Jain, V. K.; Purohit, S. C.; pohlit, W. Optimization of cancer therapy-Part I. Inhibition of repair of X-ray induced potentially lethal damage by 2-deoxy-D-glucose in Ehrlich ascites tumor cells. Ind. J. Expt. Biol. 15: 711-713; 1977.